Bioporto CEO despite growing deficit: ”A fantastic six months”

Bioporto’s sales of antibodies and the kidney test NGAL for research use have grown rapidly in 2017. Despite this, the company is forced to downgrade its financial expectations, now expecting a larger deficit for the year. But there is a perfectly good reason for that, explains the CEO.

Photo: BioPorto PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Omstridt parallelimportør går konkurs

Parallelimportøren Europharma, der to gange i 2017 blev suspenderet af Lægemiddelstyrelsen, er gået konkurs. Selskabet har erkendt, at et varelager for 50 mio. kr. er usælgeligt.

Related articles